A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Miller, V. A.; O'Connor, P.; Soh, C.; Kabbinavar, F.; for the ATLAS Investigators |
| Abstract Title: | A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) |
| Meeting Title: | 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 27 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2009 May 29-Jun 2 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2009-06-20 |
| Start Page: | 799s |
| Language: | English |
| ACCESSION: | WOS:000276607000033 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2009.27.18_suppl.lba8002 |
| Notes: | Meeting Abstract: 8002 -- Source: Wos |
